相关实验视频
Updated: Nov 30, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
抑制PCSK9增强了癌症的免疫检查点治疗
Xinjian Liu1,2, Xuhui Bao1, Mengjie Hu1
1Department of Dermatology, Duke University Medical Center, Durham, NC, USA.
抑制9型蛋白转化酶 (PCSK9) 通过增加瘤细胞MHC I表达来增强癌症免疫检查点治疗,从而促进T细胞反应. 这种方法有望改善患者的治疗结果.
科学领域:
- 免疫学
- 癌症学
- 分子生物学
背景情况:
- 免疫检查点治疗改善了部分癌症患者的存活率,但对许多患者无效.
- 需要新的策略来提高免疫检查点抑制剂的有效性.
- 蛋白转化酶9型 (PCSK9) 是胆固醇代谢的关键调节剂.
研究的目的:
- 调查抑制PCSK9是否可以增强对癌症免疫检查点治疗的反应.
- 阐明PCSK9抑制影响抗瘤免疫力的机制.
主要方法:
- 在小鼠癌细胞中遗传删除PCSK9基因.
- 在小鼠癌症模型中使用PCSK9中和抗PD1疗法.
- 评估瘤生长,T细胞反应和主要组织相容性蛋白 I (MHC I) 表达.
主要成果:
- 删除PCSK9基因减弱了T细胞依赖的瘤生长,并增强了抗PD1治疗的疗效.
- 临床批准的PCSK9抗体与抗PD1疗法协同抑制瘤生长.
- 抑制PCSK9增加了瘤细胞上的MHC I表面表达,促进了细胞毒性T细胞的透.
结论:
- 通过独立于其胆固醇调节功能的机制,抑制PCSK9增强了抗瘤免疫力.
- PCSK9在物理上与MHC I相互作用,促进其溶酶体降解并减少细胞表面表达.
- 抑制PCSK9是一种有前途的策略,可以提高癌症免疫检查点治疗的有效性.
更多相关视频
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
相关概念视频
Tumor Immunotherapy
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...